ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2013
Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 78 citations in OpenAlex.
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.JAMA neurology · 2015Trial
- Loss of miR-145 promotes remyelination and functional recovery in a model of chronic central demyelination.Communications biology · 2024Article
- Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: focus on multiple sclerosis.Molecular biology reports · 2024Article
- Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis.Archivum immunologiae et therapiae experimentalis · 2023Article
- The Journey of iPSC-derived OPCs in Demyelinating Disorders: FromCurrent neuropharmacology · 2023Article
- The use of patient-specific stem cells in different autoimmune diseases.Saudi journal of biological sciences · 2022Review
- Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.Multiple sclerosis and related disorders · 2020Review
- Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.AJNR. American journal of neuroradiology · 2017Review
- Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Review
- Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Current treatment options in neurology · 2017Review
- Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.Journal of clinical & cellular immunology · 2016Article
- Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?Stem cell research & therapy · 2016Review
- The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.Advanced biomedical research · 2016Review
- Disease-modifying treatments for multiple sclerosis - a review of approved medications.European journal of neurology · 2016Review
- MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- [Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].Der Nervenarzt · 2015Observational
- Aggressive multiple sclerosis: proposed definition and treatment algorithm.Nature reviews. Neurology · 2015Review
- Structural properties of scaffolds: Crucial parameters towards stem cells differentiation.World journal of stem cells · 2015Review
- The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Progress in neurobiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports from more than 600 hematopoietic stem cell transplants (HSCT) have appeared in the medical literature for the last 1 and one-half decades. The patient's own stem cells are harvested and stored temporarily while high doses of chemotherapy and biologics are used to destroy the auto-destructive immune system. The immune system is regenerated from the infused autologous hematopoietic stem cells. Increasing clinical experience has refined patient selection criteria and management in the peri-transplant period leading to a reduction in treatment-related complications. HSCT, when used to treat patients with aggressive highly active multiple sclerosis, can reduce or eliminate ongoing clinical relapses, halt further progression, and reduce the burden of disability in some patients, in the absence of chronic treatment with disease-modifying agents. The top 10 lessons learned from the growing experience using HSCT for the treatment of multiple sclerosis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.